Analysis of tumor mutational burden, progression-free survival, and local-regional control in patents with locally advanced non-small cell lung cancer treated with chemoradiation and durvalumab Journal Article
| Authors: | Lebow, E. S.; Shepherd, A.; Eichholz, J. E.; Offin, M.; Gelblum, D. Y.; Wu, A. J.; Simone, C. B. 2nd; Schoenfeld, A. J.; Jones, D. R.; Rimner, A.; Chaft, J. E.; Riaz, N.; Gomez, D. R.; Shaverdian, N. |
| Article Title: | Analysis of tumor mutational burden, progression-free survival, and local-regional control in patents with locally advanced non-small cell lung cancer treated with chemoradiation and durvalumab |
| Abstract: | Importance: The addition of consolidative durvalumab to chemoradiation has improved disease control and survival in locally advanced non-small cell lung cancer (NSCLC). However, there remains a need to identify biomarkers for response to this therapy to allow for risk adaptation and personalization. Objectives: To evaluate whether TMB or other variants associated with radiation response are also associated with outcomes following definitive chemoradiation and adjuvant durvalumab among patients with locally advanced unresectable NSCLC. Design, Setting, and Participants: This cohort study included consecutive patients with unresectable locally advanced NSCLC treated with chemoradiation and adjuvant durvalumab between November 2013 and March 2020 who had prospective comprehensive genomic profiling. This study was completed at a multisite tertiary cancer center. The median (IQR) follow-up time was 26 (21-36) months. Statistical analysis was conducted from April to October 2022. Exposures: Patients were grouped into TMB-high (≥10 mutations/megabase [mt/Mb]) and TMB-low (<10 mt/Mb) groups and were additionally evaluated by the presence of somatic alterations associated with radiation resistance (KEAP1/NFE2L2) or radiation sensitivity (DNA damage repair pathway). Main Outcomes and Measures: The primary outcomes were 24-month local-regional failure (LRF) and progression-free survival (PFS). Results: In this cohort study of 81 patients (46 [57%] male patients; median [range] age, 67 [45-85] years), 36 patients (44%) had TMB-high tumors (≥10 mt/Mb). Patients with TMB-high vs TMB-low tumors had markedly lower 24-month LRF (9% [95% CI, 0%-46%] vs 51% [95% CI, 36%-71%]; P =.001) and improved 24-month PFS (66% [95% CI, 54%-84%] vs 27% [95% CI, 13%-40%]; P =.003). The 24-month LRF was 52% (95% CI, 25%-84%) among patients with KEAP1/NFE2L2-altered tumors compared with 27% (95% CI, 17%-42%) among patients with KEAP1/NFE2L2-wildtype tumors (P =.05). On Cox analysis, only TMB status was associated with LRF (hazard ratio [HR], 0.17; 95% CI, 0.03-0.64; P =.02) and PFS (HR, 0.45; 95% CI, 0.21-0.90; P =.03). Histology, disease stage, Eastern Cooperative Oncology Group status, programmed cell death ligand 1 expression, and pathogenic KEAP1/NFE2L2, KRAS, and DNA damage repair pathway alterations were not significantly associated with LRF or PFS. Conclusions and Relevance: In this cohort study, TMB-high status was associated with improved local-regional control and PFS after definitive chemoradiation and adjuvant durvalumab. TMB status may facilitate risk-adaptive radiation strategies in unresectable locally advanced NSCLC.. © 2023 American Medical Association. All rights reserved. |
| Keywords: | aged; genetics; prospective study; prospective studies; cohort studies; carcinoma, non-small-cell lung; lung neoplasms; cohort analysis; tumor marker; lung tumor; non small cell lung cancer; progression-free survival; transcription factor nrf2; kelch like ech associated protein 1; humans; human; male; female; durvalumab; biomarkers, tumor; nf-e2-related factor 2; kelch-like ech-associated protein 1 |
| Journal Title: | JAMA Network Open |
| Volume: | 6 |
| Issue: | 1 |
| ISSN: | 2574-3805 |
| Publisher: | American Medical Association |
| Date Published: | 2023-01-01 |
| Start Page: | e2249591 |
| Language: | English |
| DOI: | 10.1001/jamanetworkopen.2022.49591 |
| PUBMED: | 36602799 |
| PROVIDER: | scopus |
| PMCID: | PMC9856786 |
| DOI/URL: | |
| Notes: | Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed -- MSK corresponding author is Narek Shaverdian -- Export Date: 1 February 2023 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work